Biosimilar Stakeholders To Court: Flip Ruling On Market Notification

A number of industry stakeholders have filed briefs weighing in on appeals by Amgen and Sandoz for an en banc federal appeals court hearing of their litigation concerning the biosimilar pathway, with many fellow biosimilar companies siding with Sandoz in its push for a reversal of the court's ruling that the law's 180-day marketing notice is only effective after licensure. Amgen is seeking reversal of the patent dance piece of the decision. The two companies appealed to have the full...